BPC-157 + TB-500 (20mg)
A blend of BPC-157 (10 mg) and TB-500 (10 mg) — a larger 20 mg vial for extended, intensive healing protocols. BPC-157 is a pentadecapeptide that enhances angiogenesis via VEGF/PDGF, while TB-500 (Thymosin Beta-4) promotes cell migration through actin regulation. Administered subcutaneously once daily with gradual titration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
BPC-157 enhances VEGF/PDGF signaling and nitric oxide (NO) pathways, increasing angiogenesis and fibroblast migration into damaged tissues. Preclinical models report accelerated healing of gut, tendon, ligament, and muscle injuries. TB-500 regulates actin, facilitating cell migration, while simultaneously reducing fibrosis and scar tissue. Together, they provide faster and more organized healing through complementary mechanisms — local (BPC-157) and systemic (TB-500) tissue repair.
Quick Start
- Reconstitution: Add 2.0 mL of bacteriostatic water → 10 mg/mL (5 mg/mL per peptide).
- Typical daily range: 500–2,000 mcg total once daily (gradual titration).
- Storage: Lyophilized: freeze at −20 °C · post-reconstitution: refrigerate at 2–8 °C · use within 4 weeks.
8-Week Titration Protocol (2 mL = 10 mg/mL)
Route: Subcutaneously | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 5 Units (0.05 mL) |
| Weeks 3–4 | 1,000 mcg (1.0 mg) | 10 Units (0.10 mL) |
| Weeks 5–8 | 2,000 mcg (2.0 mg) | 20 Units (0.20 mL) |
Studies report administration once daily subcutaneously. Cycle 4–8 weeks, followed by a 2–4 week pause. The larger vial (20 mg) is more cost-effective for extended protocols or higher doses. For doses ≤5 units (≤0.05 mL), use 30-unit syringes.
Reconstitution Steps
- Withdraw 2.0 mL of bacteriostatic water with a sterile syringe (ideally a 3 mL syringe with a 21–23 gauge needle).
- Slowly inject down the side of the vial, letting the water run down the glass wall; avoid foaming.
- Gently swirl or rotate until fully dissolved (do not shake vigorously — it destroys peptide bonds).
- Note the reconstitution date and concentration (10 mg/mL) on the vial; refrigerate at 2–8 °C, protecting from light.
Protocol Overview
- Objective: Intensive tissue healing via the synergistic action of BPC-157 (angiogenesis) + TB-500 (cell migration).
- Schedule: Daily subcutaneous injections for 4–8 weeks, followed by a 2–4 week pause.
- Storage: Lyophilized frozen · reconstituted refrigerated · use within 4 weeks.
Dosing Protocol
- Start: 500 mcg daily (5 units) · low dose to assess individual tolerance.
- Increase: 1,000 mcg daily (10 units) in weeks 3–4.
- Target: 2,000 mcg daily (20 units) in weeks 5–8 — suitable for severe injuries.
- Frequency: Once daily (subcutaneously).
- Cycle Duration: 4–8 weeks on, 2–4 weeks off · inject near the injury site if feasible.
- Break between cycles: After the cycle, a 2–4 week pause is recommended before repeating. The pause helps prevent tolerance (tachyphylaxis) and restore natural healing mechanisms.
Washout & Cycle Restart
When can I restart?
After the cycle, a 2–4 week pause is recommended before repeating. The pause helps prevent tolerance (tachyphylaxis) and restore natural healing mechanisms.
Minimum wait period: 2 weeks
Storage Instructions
- Lyophilized: Store at −20 °C in dry, dark conditions.
- Reconstituted: Refrigerate at 2–8 °C · use within 4 weeks · avoid freeze-thaw cycles.
- Allow frozen vials to reach room temperature before opening.
Important Notes
- Injecting near the injured tissue may enhance local results.
- Human clinical data remain preliminary; health decisions should be made with a healthcare professional.
Potential Benefits & Side Effects
Potential Benefits:
- Stronger dosing for severe injuries compared to the 10 mg vial.
- Synergistic angiogenesis and cell migration across multiple tissues.
- Reduction in scar tissue and improved quality of regenerated tissue.
- Anti-inflammatory action and pain reduction.
- More cost-effective per mg compared to smaller vials.
Potential Side Effects:
- Generally very well tolerated in preclinical studies.
- Potential mild injection site reaction (redness, itching, transient discomfort).
- Human clinical data remain limited; long-term safety has not been established.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical concern: angiogenesis & oncogenesis
BPC-157 promotes angiogenesis (VEGF upregulation). May theoretically enhance blood supply to existing tumors. No clinical data in humans.
📄 J Physiol Pharmacol 2010Theoretical concern: angiogenesis
Thymosin β4 regulates angiogenesis and cell migration. Theoretical concern that it may favor growth of existing tumors, though no clinical evidence exists.
📄 Ann NY Acad Sci 2007References
- HSS Journal (PMC) — BPC-157 in orthopaedic sports medicine: a systematic review (2025)
View Source - Expert Opinion on Biological Therapy — TB-500 (Thymosin β4) regenerative properties
View Source - Frontiers in Endocrinology (2021) — Progress in Thymosin β4 function and application
View Source - Current Pharmaceutical Design (PMC) — BPC-157: a stable gastric pentadecapeptide with healing properties
View Source - Life Sciences — BPC-157 and angiogenic growth factors
View Source
External Sources & Regulatory Status
Regulatory Approvals
Research-only — No regulatory approval (extensive preclinical research)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →